Integrative Oncology: Which Complementary Therapies Have Cancer Evidence?

80% of Cancer Patients Use Complementary Therapies. Few Tell Their Oncologist.

A systematic review published in the Journal of the National Cancer Institute in 2019 found that approximately 80% of cancer patients in the United States use some form of complementary or alternative medicine during their cancer treatment. The same literature consistently documents that only 30–50% of these patients disclose this use to their oncologists. The gap has consequences: some complementary therapies meaningfully reduce treatment-related side effects and improve quality of life with strong evidence supporting their use. Others, particularly certain herbal supplements and high-dose antioxidants, may interfere with chemotherapy efficacy or cause direct organ toxicity. Integrative oncology — the subspecialty that systematically evaluates and incorporates evidence-based complementary approaches into cancer care — exists to navigate this landscape with clinical rigor.

Defining Integrative Oncology

Integrative oncology is distinct from "alternative oncology," a critical distinction. Alternative medicine in cancer contexts typically refers to using unproven treatments instead of conventional therapy — an approach associated with significantly worse outcomes. A 2017 study in JAMA Oncology by Johnson et al. found that cancer patients who chose alternative medicine instead of conventional treatment had a twofold greater risk of death, with breast cancer patients who rejected conventional treatment having 5.68 times the mortality risk over a five-year period.

Integrative oncology, by contrast, uses evidence-based complementary approaches alongside standard oncology care, with explicit goals of:

• Reducing chemotherapy, radiation, and surgical side effects
• Managing cancer-related symptoms including pain, fatigue, nausea, and anxiety
• Optimizing nutritional status during treatment
• Improving overall quality of life and treatment tolerability
• Evaluating and managing safety of any non-conventional interventions patients are using

Evidence Tiers for Common Complementary Approaches

The Society for Integrative Oncology (SIO) and the American Society of Clinical Oncology (ASCO) have published joint clinical practice guidelines rating evidence for complementary interventions in cancer care. The 2022 guidelines update reflects the current state of evidence.

Mind-Body Interventions: The Strongest Evidence Base

Among all integrative oncology approaches, mind-body interventions have accumulated the most robust randomized controlled trial data for cancer patients. Mindfulness-Based Stress Reduction (MBSR), an 8-week structured program developed by Jon Kabat-Zinn, has been tested in multiple cancer populations.

• A 2004 RCT by Speca et al. in Psychosomatic Medicine found MBSR reduced mood disturbance by 65% and stress symptoms by 35% in cancer patients compared to waitlist controls
• A 2013 meta-analysis of 22 studies involving 1,403 cancer patients found mindfulness interventions significantly reduced anxiety, depression, fatigue, and sleep disturbance with moderate effect sizes
• Yoga in breast cancer survivors has Grade A evidence (per SIO) for reducing anxiety; a 2012 Cochrane review found yoga produced significant improvements in emotional function, fatigue, and global health status
• These interventions work through documented mechanisms: reduction of hypothalamic-pituitary-adrenal axis hyperactivation, reduction in inflammatory cytokine levels (IL-6, TNF-alpha), and improved vagal tone

Nutritional Interventions: What Works and What Doesn't

Nutrition during cancer treatment is a legitimate integrative oncology domain with real clinical stakes. Malnutrition affects 30–85% of cancer patients depending on tumor type and treatment, and is independently associated with worse outcomes.

• Omega-3 fatty acids (EPA/DHA): Multiple RCTs show supplementation reduces cancer cachexia (muscle wasting) and improves nutritional status; 2022 meta-analysis supports 2g/day EPA for preservation of lean body mass during treatment
• Vitamin D: Deficiency is common in cancer patients; supplementation to correct deficiency is standard; whether supraphysiologic doses improve cancer outcomes remains under investigation in large trials
• Ginger supplements: A 2009 RCT (Ryan et al., Supportive Care in Cancer) found 0.5–1g ginger daily significantly reduced acute chemotherapy-induced nausea vs. placebo
• High-dose vitamin C (IV): Used in some integrative oncology programs; limited but suggestive evidence that high-dose IV vitamin C may improve quality of life and reduce fatigue; not established as an anticancer treatment; may be contraindicated with certain chemotherapies

Supplements That May Harm: The Interaction Problem

The most clinically important role of integrative oncology physicians is identifying supplements that may reduce treatment efficacy or cause organ toxicity during conventional cancer treatment.

The integrative oncology framework does not endorse all natural products and does not oppose conventional treatment. Its value lies in applying systematic evidence evaluation to a domain where patients are making complex decisions, often without adequate clinical guidance. The goal is not to choose between ancient wisdom and modern medicine. It is to use what actually works — proven in trials, measured in outcomes, offered to patients alongside rather than instead of effective treatment.

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.